Skip to main content

Amoxicillin-induced aseptic meningitis: clinical features, diagnosis and management



The clinical features of aseptic meningitis associated with amoxicillin are unknown. The main objective of this study was to investigate the clinical characteristics of amoxicillin-induced aseptic meningitis (AIAM) and provide a reference for clinical diagnosis and treatment.


AIAM-related studies were collected by searching the relevant databases from inception to October 31, 2022.


AIAM usually occurred 3 h to 7 days after amoxicillin administration in 13 males and 9 females. Twenty-one patients (95.5%) had recurrent AIAM with a total of 62 episodes. Fever (19 cases, 86.4%) and headache (18 cases, 81.8%) were the most common symptoms. Typical cerebrospinal fluid (CSF) findings were leukocytosis (100%) with lymphocytic predominance (14 cases, 63.6%), elevated protein (20 cases, 90.1%), normal glucose (21 cases, 95.5%) and negative culture (21 cases, 100%). Brain magnetic resonance imaging showed mild meningeal enhancement in one patient. The symptoms resolved mainly within 1–4 days after drug discontinuation in all patients.


Clinical attention should be given to the adverse effects of AIAM. The medication history of patients with suspected meningitis should be investigated to avoid unnecessary examination and antibiotic treatment.


Meningitis is characterized by diffuse inflammatory changes in the pia mater caused by various biological pathogenic factors, such as bacteria, viruses, fungi or protozoa, tumors, cancers, and autoimmune systemic diseases invading the pia mater and spinal cord membrane [1,2,3]. Aseptic meningitis (AM) is defined as the absence of evidence of pathogen infection but the presence of associated neurological symptoms and cytological abnormalities in the cerebrospinal fluid (CSF) [4]. Drugs are an important factor in AM, including nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, intravenous immunoglobulin, antiepileptic drugs, and monoclonal antibodies [5].

The incidence of drug-induced aseptic meningitis (DIAM) remains unreported. Antibiotic-associated DIAM is most often caused by trimethoprim with or without sulfamethoxazole and penicillin-derived antibiotics [5, 6]. Analysis of 329 cases of drug-induced aseptic meningitis showed that 11% of the drugs were antibiotics, of which amoxicillin accounted for 5% [7]. The incidence, pathogenesis, treatment and prevalence of amoxicillin-induced aseptic meningitis (AIAM) are not widely reported. Knowledge of AIAM is limited to individual reports. AIAM has not been labeled as a potential adverse effect in most countries. Assessment of AIAM is still variable today and is a diagnostic and management dilemma for clinicians. Here, we collected case reports of AIAM, explored its clinical features, and provided a reference for clinical diagnosis and treatment.


Retrieval strategy

We collected case reports, case series, clinical studies and reviews of amoxicillin-induced aseptic meningitis by searching Chinese databases (Wanfang, China VIP, CNKI) and English databases (PubMed, Embase, Cochrane) from establishment to October 31, 2022. The searches were performed using subject and free words, including “amoxicillin” [MeSH] OR “amoxicillin-clavulanate” [MeSH] OR “antibiotics” [MeSH] OR “β-lactam antibiotics” OR “drug” AND “meningitis” [MeSH] OR “aseptic meningitis” [MeSH] OR “drug-induced aseptic meningitis” [MeSH] AND “headache” [MeSH] AND “pharmacovigilance” [MeSH].

Inclusion and exclusion criteria

Case reports and clinical study series were included. Reviews, basic studies, replication studies, and studies of other antibiotic-induced AM were excluded.

AIAM definition

AIAM was defined as the time relationship with amoxicillin-containing products, CSF leukocytosis (> 5 cells/µl), negative culture, and symptom recovery after drug withdrawal. For patients with several episodes, we selected the most recent episode for data extraction.

Data Extraction

Two independent authors collected patients' nationality, sex, age, drug usage and dosage, meningitis symptoms, neuroimaging results, cerebrospinal fluid results, treatment regimens and clinical outcomes and then summarized the data. For patients with several episodes, we selected the most recent episode for data extraction.


Basic data

The literature screening process is shown in Fig. 1. A total of 22 patients with AIAM from 20 articles were included [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27]. The basic information of the 22 patients is summarized in Table 1. The median age of 9 females and 13 males was 62.5 years (range 30–86), and the patients were mainly from Europe (14 cases, 63.6%), North America (6 cases, 27.3%), and Asia (2 cases, 9.1%). Of the 22 patients, 13 (59.1%) received amoxicillin, and 9 (40.9%) received amoxicillin clavulanate. The onset time of symptoms varied from 3 h to 7 d after administration. Six patients (27.3%) exhibited symptoms within 12 h after administration, 10 patients (45.5%) after 1 to 3 days, and 5 patients (22.7%) after 4 to 7 days.

Fig. 1
figure 1

Flowchart of the study selection process for reported cases of amoxicillin-induced aseptic meningitis

Table 1 Basic information of the 22 patients included

Two patients (9.1%) had a history of multiple food allergies. Of the 16 patients (27.3%) for whom the administration method was described, 15 (68.2%) were administered orally, and 1 patient (4.5%) was administered by intravenous injection. Both amoxicillin and amoxicillin clavulanate doses were within the recommended range in the 10 patients (45.5%) with records.

Clinical symptoms

The clinical data of 22 patients are shown in Table 2. Twenty-one patients (95.5%) had recurrent AIAM with a total of 62 episodes, with a maximum of 7 episodes in one patient (4.5%). Patients usually presented with fever (19 cases, 86.4%), headache (18 cases, 81.8%), nuchal rigidity (7 cases, 31.8%), photophobia (6 cases, 27.3%) and nausea (6 cases, 27.3%). Headache was severe and progressive, with two patients (9.1%) presenting with pressure-like global headache and one patient presenting with occipital pain. Other symptoms included vomiting (4 cases, 18.2%), myalgia (4 cases, 18.2%), chills (3 cases, 13.6%), and phonophobia (2 cases, 9.1%). Rare complications included behavioral confusion, aphasia, apraxia, coma, lethargy, difficulty walking, weakness, and diarrhea.

Table 2 Clinical manifestations, cerebrospinal fluid examination results, treatment and prognosis of the 22 included patients

Laboratory tests and brain imaging

CSF examination of 21 patients found that glucose was normal (21 cases, 100%); protein was elevated in 20 cases (95.2%) and normal in 1 case (4.8%). The median value of protein was 91 mg/dL (range: 41–2560). Cytological analysis of CSF revealed leukocytosis in 22 patients, including 14 patients (63.6%) with lymphocytosis, 4 patients (18.2%) with monocytosis, and 3 patients (13.6%) with neutrophilia. Red blood cells were found in 3 patients (13.6%).

Among the 22 patients, 18 patients underwent magnetic resonance imaging (MRI) examination; 17 patients showed no abnormality, and 1 patient showed mild meningeal enhancement on MRI. Computed tomography (CT) was performed in 17 patients with no abnormalities. CSF cultures found no evidence of bacteria or viruses in 22 patients.

Treatment and prognosis

Amoxicillin and amoxicillin clavulanate were eventually discontinued in all patients. Ten patients (45.5%) received empirical antibiotic treatment. Meningitis symptoms recovered in 20 patients (90.9%) within 12h-14d after drug withdrawal, and the clinical outcome was not described for 2 patients (9.1%).


DIAM is a rare entity, and the onset time is variable, ranging from a few minutes to several months [28, 29]. Moreover, clinical signs and cerebrospinal fluid examination results vary greatly. The clinical manifestations are consistent with meningoencephalitis, including fever, headache, photophobia, neck stiffness, nausea, vomiting, and myalgia [30]. AIAM appeared at 3 h ~ 7 d after administration. DIAM may initially be confused with viral or bacterial meningitis. If other inducements are excluded, the diagnosis of DIAM is based on the time between administration and symptom onset and the rapid disappearance of symptoms after drug withdrawal. Several pathophysiological factors may contribute to DIAM, such as autoimmune disease, migraine, immune dysregulation and genetic predisposition [31]. Meningitis was caused by intravenous penicillin in one woman [32]. Cephalosporins, including cefazolin, ceftriaxone and ceftazidime, are also associated with aseptic meningitis. [7] One woman developed several episodes of aseptic meningitis due to exposure to cefalexin, cefazolin, and ceftazidime [33]. This patient should avoid cephalosporins and consider herself cross-allergic to them. It is not known whether AIAM would show cross sensitivity with other penicillins, and we suggest that it would be advisable to avoid the use of other penicillins in patients who have been diagnosed with AIAM.

The pathophysiology of DIAM is unclear, and two main mechanisms may be involved. One is the direct toxicity of drugs, and the other is related to immune hypersensitivity [30]. The current study suggests that AIAM may be a delayed type 4 hypersensitivity reaction or T-cell-mediated hypersensitivity reaction. Laboratory results in one AIAM patient did not support type I or type III reactions, and no specific IgE or C1q were detected [15]. T-cell activation was detected in another 2 AIAM patients [27]. The occurrence of AIAM independent of amoxicillin dose may indicate that this is an allergic reaction. Men are at higher risk for AIAM than women. A possible explanation is that the immune response differs by sex. [34]

In our study, we found that fever and headache were the most common complaints. Five patients developed symptoms of meningoencephalitis, characterized by neurological symptoms such as disturbances of consciousness and coma. CSF examination results vary in different DIAM cases, usually in terms of CSF cytosis, which is mainly neutrophilic, but some patients have CSF lymphocytosis and eosinophilia with unchanged leucocytes. Protein levels in the CSF are usually high, while glucose levels are normal, although some cases are described as having reduced glucose levels [35]. The typical CSF manifestation of AIAM is neutrophilic lymphocytosis, and the number of white blood cells is tens to hundreds per microliter, with normal glucose levels and variably elevated protein levels. In general, clinical symptoms and cerebrospinal fluid findings are not helpful in distinguishing between drug-induced aseptic meningitis and bacterial meningitis. Blood tests and brain CT or MRI scans were not diagnostic. Determining the temporal relationship between amoxicillin use and aseptic meningitis is critical for diagnosis. Compared with bacterial meningitis patients, the CSF glucose level of AIAM patients is usually lower, while that of DIAM patients is normal [36]. Another difference between bacterial meningitis and DIAM is the high level of C-reactive protein (CRP). The symptoms of DIAM usually recover within 10–14 days, which is different from viral meningitis [18]. However, the symptoms of AIAM disappeared within 7 days.

The causative drug needs to be discontinued in cases of DIAM [30]. Symptoms associated with meningitis can be given symptomatic treatment, such as pain relievers for headache and antiemetic drugs for nausea and vomiting. Patients with immunoglobulin (IVIG)-related DIAM received hydration, analgesics, and systemic corticosteroids [37,38,39]. Antitumor necrosis factor drugs were also considered in some serious cases [40]. However, there was no significant difference in the clinical course, regardless of whether the patient received treatment.

AIAM is reversible and usually does not require any further treatment after drug withdrawal. When AIAM is suspected, the drug should be discontinued if possible. A third-generation cephalosporin may be given empirically to avoid any risk of infection until CSF results are available [31]. AIAM patients may relapse after challenge. We do not recommend that patients rechallenge amoxicillin or amoxicillin clavulanic acid in cases of previous aseptic meningitis. Rechallenging amoxicillin or amoxicillin clavulanate potassium can lead to a recurrence of aseptic meningitis.


There are some limitations to our study. First, the sample size was small, our study was limited to case series and single case reports, and statistical analysis was hampered, making it difficult to confirm or disprove certain clinical features associated with AIAM. Second, the level of detail provided was different in each case. Therefore, it is subject to a certain degree of data interpretation. Despite its limitations, we believe that this study still has some reference value.


There is a possible association between amoxicillin-containing products and the risk of aseptic meningitis. Identifying AIAM is a challenge, and patients with meningitis should be asked about their medication history in detail to avoid unnecessary testing and treatment.

Availability of data and materials

The data used to support the findings of this study are included within the article.


  1. Logan SA, MacMahon E. Viral meningitis. BMJ. 2008;336(7634):36–40.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Marinac JS. Drug- and chemical-induced aseptic meningitis: a review of the literature. Ann Pharmacother. 1992;26(6):813–22.

    Article  CAS  PubMed  Google Scholar 

  3. Chaudhry HJ, Cunha BA. Drug-induced aseptic meningitis. Diagnosis leads to quick resolution. Postgrad Med. 1991;90(7):65–70.

    Article  CAS  PubMed  Google Scholar 

  4. Tapiainen T, Prevots R, Izurieta HS, Abramson J, Bilynsky R, Bonhoeffer J, et al. Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine. 2007;25(31):5793–802.

    Article  CAS  PubMed  Google Scholar 

  5. Hopkins S, Jolles S. Drug-induced aseptic meningitis. Expert Opin Drug Saf. 2005;4(2):285–97.

    Article  CAS  PubMed  Google Scholar 

  6. Kalmi G, Javeri F, Vanjak A, Kirren Q, Green A, Jarrin I, Lloret-Linares C. Drug-induced meningitis: A review of the literature and comparison with an historical cohort of viral meningitis cases. Therapie. 2020;75(6):605–15.

    Article  PubMed  Google Scholar 

  7. Bihan K, Weiss N, Théophile H, Funck-Brentano C, Lebrun-Vignes B. Drug-induced aseptic meningitis: 329 cases from the french pharmacovigilance database analysis. Br J Clin Pharmacol. 2019;85(11):2540–6.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Sousa D, Raimundo P. Amoxicillin-induced aseptic meningitis. Eur J Case Rep Intern Med. 2020;7(6): 001543.

    PubMed  PubMed Central  Google Scholar 

  9. Turk VE, Simić I, Makar-Aušperger K, Radačić-Aumiler M. Amoxicillin-induced aseptic meningitis: case report and review of published cases. Int J Clin Pharmacol Ther. 2016;54(9):716–8.

    Article  PubMed  Google Scholar 

  10. Chu L, Eustace M. Recurrent Amoxicillin-Induced Aseptic Meningitis. Can J Neurol Sci. 2018;45(6):701–2.

    Article  PubMed  Google Scholar 

  11. Leh F, Edan G, Jego P, Perlat A, Oger E, Bellissant E, Polard E. Amoxicillin-induced meningitis. Fundam Clin Pharmacol. 2012;26(Suppl. 1):110.

    Google Scholar 

  12. Thaunat O, Gilquin J, Lazareth I, Priollet P. Amoxicillin-induced aseptic meningoencephalitis. Allergy. 2003;58(7):687–8.

    Article  CAS  PubMed  Google Scholar 

  13. Czerwenka W, Gruenwald C, Conen D. Aseptic meningitis after treatment with amoxicillin. BMJ. 1999;318(7197):1521.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Mateos V, Calleja S, Jiménez L, Suárez-Moro R. Recurrent aseptic meningitis associated with amoxicillin-clavulanic acid. Med Clin (Barc). 2000;114(2):79.

    Article  CAS  PubMed  Google Scholar 

  15. Kastenbauer S, Pfister HW, Wick M. No evidence of type 1 or type 3 hypersensitivity mechanism in amoxicillin/clavulanic acid induced aseptic meningitis. J Neurol Neurosurg Psychiatry. 2003;74(5):690–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Whyte CA, Shivdat-Nanhoe R, Kramer P. A case of amoxicillin-induced meningitis. Clin Infect Dis. 2008;46(4):642.

    Article  PubMed  Google Scholar 

  17. River Y, Averbuch-Heller L, Weinberger M, Meiner Z, Mevorach D, Schlesinger I, Argov Z. Antibiotic induced meningitis. J Neurol Neurosurg Psychiatry. 1994;57(6):705–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shahien R, Vieksler V, Bowirrat A. Amoxicillin-induced aseptic meningoencephalitis. Int J Gen Med. 2010;3:157–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Strom J, Cooper C. An unusual case of meningitis. J Hosp Med. 2012;7(Suppl 2):328.

    Google Scholar 

  20. Leung J, Wilson M. Amoxicillin-induced aseptic meningitis with neutrophil predominance. J Allergy Clin Immunol. 2012;129:236.

    Article  Google Scholar 

  21. Wittmann A, Wooten GF. Amoxicillin-induced aseptic meningitis. Neurology. 2001;57(9):1734.

    Article  CAS  PubMed  Google Scholar 

  22. Ponte CD, Unger K. A suspected case of amoxicillin-associated aseptic meningitis. J Pharm Technol. 2021;37(3):165–6.

    Article  PubMed  Google Scholar 

  23. Alarcón E, Sansosti A, Navarro B, Claver Á, Botey E, Cisteró-Bahima A, Bartra J. Amoxicillin-induced aseptic meningitis: 2 case reports and appraisal of the literature. J Investig Allergol Clin Immunol. 2019;29(3):248–50.

    Article  PubMed  Google Scholar 

  24. Garrido JP, Tejada Marín JW, Vélez Londoño JD, et al. Amoxicillin as possible cause of aseptic meningitis: a case report and literature review. Infectio. 2017;21(1):65–8.

    Google Scholar 

  25. Alarcón E, Sansosti A, Botey E, Peña M, Navarro B, Claver Á, Cisteró-Bahima A. Drug-induced aseptic meningitis due to amoxicillin. Allergy: Eur J Allergy Clin Immunol. 2015;70(101):524–5.

    Google Scholar 

  26. Prieto-González S, Escoda R, Coloma E, Grau JM. Amoxicillin-induced acute aseptic meningitis. J Clin Neurosci. 2011;18(3):443–4.

    Article  PubMed  Google Scholar 

  27. Castagna J, Nosbaum A, Vial T, Rozieres A, Hacard F, Vocanson M, et al. Drug-induced aseptic meningitis: a possible T-cell-mediated hypersensitivity. J Allergy Clin Immunol Pract. 2018;6(4):1409–11.

    Article  PubMed  Google Scholar 

  28. Kepa L, Oczko-Grzesik B, Stolarz W, Sobala-Szczygiel B. Drug-induced aseptic meningitis in suspected central nervous system infections. J Clin Neurosci. 2005;12(5):562–4.

    Article  CAS  PubMed  Google Scholar 

  29. Morís G, Garcia-Monco JC. The challenge of drug-induced aseptic meningitis revisited. JAMA Intern Med. 2014;174(9):1511–2.

    Article  PubMed  Google Scholar 

  30. Jolles S, Sewell WA, Leighton C. Drug-induced aseptic meningitis: diagnosis and management. Drug Saf. 2000;22(3):215–26.

    Article  CAS  PubMed  Google Scholar 

  31. Moris G, Garcia-Monco JC. The challenge of drug-induced aseptic meningitis. Arch Intern Med. 1999;159(11):1185–94.

    Article  CAS  PubMed  Google Scholar 

  32. Farmer L, Echlin FA, Loughlin WC, Breakey AS, Duvoisin R. Pachymeningitis apparently due to penicillin hypersensitivity. Ann Intern Med. 1960;52:910–4.

    Article  CAS  PubMed  Google Scholar 

  33. Creel GB, Hurtt M. Cephalosporin-induced recurrent aseptic meningitis. Ann Neurol. 1995;37(6):815–7.

    Article  CAS  PubMed  Google Scholar 

  34. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–38.

    Article  CAS  PubMed  Google Scholar 

  35. Nettis E, Calogiuri G, Colanardi MC, Ferrannini A, Tursi A. Drug-induced aseptic meningitis. Curr Drug Targets Immune Endocr Metabol Disord. 2003;3(2):143–9.

    Article  CAS  PubMed  Google Scholar 

  36. van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22(Suppl 3):S37-62.

    Article  PubMed  Google Scholar 

  37. Jain RS, Kumar S, Aggarwal R, Kookna JC. Acute aseptic meningitis due to intravenous immunoglobulin therapy in Guillain-Barré syndrome. Oxf Med Case Rep. 2014;2014(7):132–4.

    Article  Google Scholar 

  38. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006;6(4):535–42.

    Article  CAS  PubMed  Google Scholar 

  39. Kemmotsu Y, Nakayama T, Matsuura H, Saji T. Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease. Pediatr Rheumatol Online J. 2011;9:28.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171–8.

    Article  PubMed  Google Scholar 

Download references


None to declare.


This study was supported by Natural Science Foundation of Hunan Province (2023JJ40499), Scientific Research Fund Project of Hunan University of Chinese Medicine (2022XYLH004).

Author information

Authors and Affiliations



ZF and CW designed research; YH, WS performed research; ZF and ZL analyzed data; ZF, CY and CW wrote the paper. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Chao Ye or Chunjiang Wang.

Ethics declarations

Ethics approval and consent to participate

This study did not require an ethical board approval because the study was a retrospective study and did not involve sensitive personal information.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fan, Z., He, Y., Sun, W. et al. Amoxicillin-induced aseptic meningitis: clinical features, diagnosis and management. Eur J Med Res 28, 301 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Aseptic meningitis
  • Drug-induced aseptic meningitis
  • Amoxicillin
  • Amoxicillin-clavulanate
  • Pharmacovigilance